Table 3.
Summary of Patients Experiencing Treatment Failure and Infection
| Patient no./age at Entry, Years/Sex | Interval from Uveitis Diagnosis to RTX Treatment (Months) | Drugs used before RTX Treatment | RTX Treatment Schedule | Outcome | Adverse Events | Remark |
|---|---|---|---|---|---|---|
| 5/32/F | 48 | MTX, CS, ETA, ADA, INFL | 375 mg/m2, 2-week apart | Active | – | No 3rd injection |
| 9/24/F | 168 | MTX, CS, AZA, ADA | 375 mg/m2, 2-week apart | Active | – | No 3rd injection |
| 10/15/F | 48 | MTX, CS, MMF, ETA, INFL, ADA | 375 mg/m2, 2-week apart | Active | – | No 3rd injection |
| 13/-/- | 132 | MTX, CS, ETA, ADA, INFL | 1000 mg × 2, 2-week apart, 3rd at 12 or 21 months | Relapse At 8th month |
– | Relapse before 3rd injection |
| 27/12/M | 120 | MTX, IND, CS, ETA, INFL, ADA, ABA | 500 mg/m2, 2-week apart | Relapse After 20 weeks |
– | B-cell depletion not enough (> 4%) |
| 30/26/F | 168 | LEF, AZA, CYC, MTX, IFN, ETA, INFL | 1000 mg × 2, 2-week apart, 3rd at 6 months | Eye enucleation | – | B-cell depletion not enough (> 3%) |
| 33/32/M | – | – | 1000 mg × 2, 2-week apart | Active | – | Active before 3rd injection |
| 61/50/M | 17 | AZA, CS | 2000 mg × 2, 2-week apart | RTX Discontinued | Pneumonia | IgG < 4 g/L,4 months |
| 68/39/F | – | MMF, RZB | 375 mg/m2 × 4 consecutive weeks | Relapse | – | – |
| 32/17/M | – | – | 1000 mg × 2, 2-week apart | Improved | Conjunctivitis | 1 week after 1st injection |
| 34/24/M | – | – | 1000 mg × 2, 2-week apart | Improved | Conjunctivitis | 1 week after 1st injection |
| 35/28/M | – | – | 1000 mg × 2, 2-week apart | Improved | Pneumonia | 4 months after 1st injection |
| 56/10/F | 40 | MTX, IFN | 375mg/m2 × 4, at 0,1,6,18 months | Inactive | Quiver | First injection |
| 62/62/F | 12 | MTX, LEF | 500 mg, 6-month apart | Inactive | COVID-19 infections |
– |
| 73/48/M | 7 | TAC | 375 mg/m2 × 8 consecutive weeks | Inactive | Toenail fungal infection | 1 year |
| 77/49/F | 36 | MMF, CS, MTX, ETA | 375 mg/m2 × 4 consecutive weeks | Inactive | Gastrointestinal discomfort | First injection |
Abbreviations: MTX, Methotrexate; CS, Cyclosporine; AZA, Azathioprine; MMF, Mycophenolate Mofetil; IND, Indomethacin; LEF, Leflunomide; IFN, Interferon; CYC, Cyclophosphamide; TAC, Tacrolimus; ETA, Etanercept; ADA, Adalimumab; INFL, Infliximab; ABA, Abatacept; RZB, Rituximab.